This site is intended only for healthcare professionals resident in India
Menu
Close
Enabling your patients to make the most of their lives1-7
Joint bleeds are associated with impairment in day-to-day activities8
Patients with hemophilia commonly experience recurrent bleeding into joints that may cause pain and arthropathy that can impact their quality of life.8
Recurrent bleeding into joints (haemarthrosis) is common in individuals with hemophilia and may cause pain and arthropathy.8
Patients reporting pain are more likely to experience anxiety and depression, worse health status and
functional impairments.9
In the prophylaxis of PTPs, 93% of responses were rated as excellent or effective (n=47).1,†
In the prophylaxis of PUPs, 91% of responses were rated as excellent‡ (n=42), indicating that spontaneous
musculoskeletal bleeding was prevented.2
Children With Hemophilia and Sport
Prophylaxis in paediatric patients supports an active lifestyle, which may reduce the bleed frequency and improve the health-related quality of life.10
A cross-sectional, multisite, study of boys aged 6 to 17 years (n=84) with hemophilia A or B§ that assessed physical performance, sporting activity and health-related quality of life found the following10,¶:
Bleeding has a variable impact on the lives of adolescent boys with hemophilia, but is most obvious in those who play sport and who have to reduced or limit their participation because of bleeding. These boys recognized that prophylaxis offered them protection from bleeding, the older and more sporty boys understood the need for tailored prophylaxis around 'risk' activities such as sport or events away from home.10
Encouraging haemophilic boys to participate in sport has a direct impact on their overall health-related quality of life.10
*Results of pooled safety data from 6 prospective studies encompassing more than 11,000 infusions of [BeneFIX®] showed that 1.2% of patients experienced inhibitors on BeneFIX® (5/412). This was considered low by study investigators.7
†The response to secondary prophylaxis was assessed once every 3 months by the investigator using a 3-point scale: Excellent (no spontaneous bleeding of any kind, no change in dosing regimen necessary); effective (no spontaneous musculoskeletal bleeding, no change in dosing regimen necessary); or inadequate (inadequate prevention of bleeding requiring a change in dosing regimen).1
‡Rated by the investigator at 3-month intervals on a 3-point scale: Excellent (prophylaxis treatment completely prevented spontaneous musculoskeletal bleeding, no change in dosing regimen necessary); effective (adequately prevented spontaneous musculoskeletal bleeding episodes as demonstrated by a lower than expected incidence of spontaneous musculoskeletal bleeding episodes); or inadequate (inadequate prevention of bleeding requiring a change in dosing regimen).2
§Of any severity, current or past inhibitor.
¶Health-related quality of life was assessed using age-appropriate questionnaires including KINDL, Haemo-QoL and HEP-Test-Q.
FIX, factor IX; Haemo-QoL, Hemophilia-Specific Quality of Life; HEP-Test-Q, Hemophilia & Exercise Project-Test-Questionnaire; IU, international unit; KINDL, German questionnaire for measuring quality of life in children and adolescents; PTP, previously treated patient; PUP, previously untreated patient.
References:
PP-BEN-IND-0025 22/07/22
See how BeneFIX® performs in real-life settings.
Review real-world data
BeneFIX® is a recombinant coagulation FIX. Find out how BeneFIX® works
Learn more
BeneFIX® provides dosing options based on individual needs
Learn more
See how BeneFIX® performs in real-life settings.
Review real-world data
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.